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The APO-1 antigen as defined by the mouse  mono- 
clonal antibody anti-APO-1  was previously found to 
be expressed on the cell surface of activated human T 
and B lymphocytes and a variety of malignant  human 
lymphoid cell lines. Cross-linking of the APO-1 antigen 
by anti-APO- 1 induced programmed cell death, apop- 
tosis, of  APO- 1 positive cells. To characterize  the APO- 
1 cell surface molecule and  to better understand  its 
role in induction of apoptosis, the APO-1 protein  was 
purified  to homogeneity from membranes of  SKW6.4 
B lymphoblastoid cells by solubilization with sodium 
deoxycholate, affinity  chromatography  with  anti- 
APO- 1 antibody, and  reversed  phase  high  performance 
liquid  chromatography. Each purification  step  was fol- 
lowed by an APO-1-specific solid phase enzyme-linked 
immunosorbent assay using the monoclonal antibody 
anti-APO- 1. In sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis, the APO- 1 antigen  was found to be 
a membrane glycoprotein of 48-kDa. Endoproteinase- 
cleaved peptides of the APO-1 protein  were subjected 
to amino acid sequencing, and corresponding oligonu- 
cleotides were used to identify a full-length APO-1 
cDNA clone from an SKW6.4  cDNA library.  The de- 
duced amino acid sequence of  APO- l showed sequence 
identity  with  the  Fas  antigen, a cysteine-rich trans- 
membrane  protein of 336 amino  acids  with  significant 
similarity  to  the members of the  tumor necrosis factor/ 
nerve  growth  factor  receptor  superfamily.  The APO-1 
antigen was expressed upon transfection of APO-1 
cDNA into  BL60-P7  Burkitt’s lymphoma cells and con- 
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ferred sensitivity  towards anti-APO- 1-induced apop- 
tosis to  the  transfectants. 
Apoptosis is  the most common form of eucaryotic cell death. 
It is found, e.g. in  tissue replacement, in organ development 
and metamorphosis, in tissue atrophy, and  in  tumor regres- 
sion. Apoptosis is induced by diverse agents such as glucocor- 
ticoids, cytostatic drugs, cytolytic cytokines such as tumor 
necrosis factor (TNF)’  and lymphotoxin, and  in  target cells 
of various killer cells including cytotoxic T lymphocytes. Its 
most prominent morphological features  are condensation of 
the chromatin and membrane blebbing (zeiosis). In many 
cells undergoing apoptosis, an endonuclease is induced that 
cuts  the genomic DNA into polynucleosomal fragments re- 
vealed on agarose gels as  a “DNA ladder” (1, 2). 
We have recently raised the mouse monoclonal antibody 
anti-APO-1, which defined a novel cell surface antigen, APO- 
1, on  activated  human T and B lymphocytes and on malignant 
human lymphoid cell lines. Anti-APO-1 binding to  the APO- 
1 antigen abrogated growth by induction of apoptosis of 
sensitive cells in vitro. Likewise, in uiuo, a single injection of 
anti-APO-1 into nu/nu mice with human lymphoid tumor 
xenotransplants eliminated these tumors by induction of 
apoptosis (3-5). 
To further  understand  anti-APO-1-induced apoptosis, the 
APO-1  antigen was characterized. We report here the purifi- 
cation of the APO-1 antigen and the isolation of a cDNA 
clone for this protein. The deduced amino acid sequence for 
APO-1 revealed a significant sequence similarity to  the mem- 
bers of the tumor necrosis factor/nerve growth factor receptor 
superfamily. Comparison of the APO-1 antigen with the re- 
cently published sequence of the  Fas antigen (6) showed that 
both molecules are identical. The  Fas antigen was originally 
defined by an  other cytolytic antibody named anti-Fas (7). 
MATERIALS AND METHODS 
APO-1 -specific  ELZSA-For detection and quantification of APO- 
1, each purification step was followed  by an ELISA. Serial dilutions 
(in HzO) of APO-1-containing samples were coated into  flat bottom 
96-well immunoassay plates (ICN Biomedicals, Meckenheim, Ger- 
~ ~~ 
The abbreviations used are: TNF, tumor necrosis factor; CHAPS, 
3-[(3-cholamidopropyl)~methylammonio]-l-propanesulfonic acid; 
ELISA, enzyme-linked immunosorbent assay; HPLC, high perform- 
ance liquid chromatography; PBS, phosphate-buffered saline; SDS, 
sodium dodecyl sulfate; PAGE, polyacrylamide gel electrophoresis; 
kb, kilobase(s); NGF, nerve growth factor. 
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10710 Purification and  Cloning of the APO-1 Antigen 
many) (100 pl final volume/well) with 0.1 volume of 1 M NaHC03, 
pH 9.6. After 2  h incubation, the liquid was removed, and  the plates 
were washed four times with 200 pl of  0.05% Tween 40 in PBS,  pH 
7.3. The washing buffer was removed, and  the bound APO-1  antigens 
were incubated with anti-APO-1 IgG2b monoclonal antibody  (2 pg/ 
ml in culture medium) for 1 h (100 pl/well). The IgG2b anti-APO-1 
class switch variant was derived from the original IgG3 anti-APO-1 
secreting hybridoma by sequential sublining. The IgG2b and  the I&3 
anti-APO-1 showed identical binding specificity toward APO-1.2 
Plates were washed again before an horseradish peroxidase-conju- 
gated goat anti-mouse IgG2b antiserum (0.5 mg/ml, Dianova, Ham- 
burg, Germany) 1:lOOO diluted in  PBS, 5% fetal calf serum, 0.05% 
Tween 40, pH 7.3, was added at  100 pllwell for 1 h. The plates were 
washed again before 75 pl of substrate buffer were added to each well 
(100 mM NazHP04, 50 mM citric acid, 0.1% orthophenylenediamine, 
0.003% H202). After 10 min, the reaction was stopped by adding 25 
pl of 3 N HzS04/well. The intensity of a given coloration was measured 
by extinction at 492  nm (Titertek Multiscan plus, Flow Laboratories, 
Meckenheim, Germany). The ELISA was carried out in duplicates. 
One unit of APO-1 antigenic activity was arbitrarily defined as  the 
amount of antigen needed to give half-maximal absorbance in  the 
ELISA. 
Purification of the APO-1 Antigen-Membranes from 5 X 10'O 
SKW6.4 cells prepared by a Tween 40 method (9) were solubilized 
with 2% sodium deoxycholate, 0.01 mM Tris-HC1, 0.1%  NaN3, 1 mM 
phenylmethylsulfonyl fluoride, pH 8.1, incubated for 1 h at  4 "C, and 
centrifuged at 100,000 X g for 1 h. The  supernatant was first applied 
to a mouse  IgG3 (FII23, IgG3 nonbinding control antibody) Sepharose 
4B column (3 mg of monoclonal antibody,  4 ml of beads) to adsorb 
nonspecific binding material. The flow-through was then applied to 
an IgG3 anti-APO-1 column (9 mg  of monoclonal antibody, 12 ml of 
beads). The anti-APO-1 affinity column was washed first with 0.1% 
sodium deoxycholate, 0.01 mM Tris-HC1, 0.1%  NaN3, 1 mM phenyl- 
methylsulfonyl fluoride, pH 8.1 (buffer l ) ,  followed by  0.15 M NaCl 
in  the above buffer and finally with buffer 1 again until absorbance 
at 280 nm returned to baseline. Bound material was eluted with 0.05 
M diethylamine/HCl, 0.1% sodium deoxycholate, 0.1% NaN3, 0.1% 
phenylmethylsulfonyl fluoride, pH 11.5, and neutralized immediately. 
Fractions with high APO-1 antigenic activity were pooled, brought to 
10% acetonitrile, and chromatographed at  1 ml  min" on  a reversed 
phase HPLC column (PLRP-S column, 300  A, 8 pm, 250 X 4.6 mm, 
Polymer Laboratories, Shropshire, UK) using a  linear  gradient from 
5-70% acetonitrile in water containing 0.1% trifluoroacetic acid. Peak 
fractions were  pooled again and subjected to a second round of HPLC 
under the above conditions. 
SDS-Polyacrylamide Gel Electrophoresis-SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE)  on 12% acrylamide gels  was performed 
as described (10). Proteins  in the gel  were visualized by silver staining 
(11). 
Protein Determination-For protein  determination, gels  were sil- 
ver-stained, and the amount of APO-1 antigen was estimated by 
comparing the intensity of the  stain with a standard protein (bovine 
serum albumin) band  stained with similar intensity. Protein concen- 
tration in  extracts was determined by the method of Bradford (12). 
Deglycosylation-200 ng of lyophilized protein samples were dis- 
solved in 20 pl of 100 mM Tris/HCl, containing 0.5% SDS, 1% 
CHAPS, 5% (3-mercaptoethanol, 10 mM EDTA, pH 7.0, denatured at  
100 "C for 2 min, and incubated with 0.3 units of endoproteinase F/ 
N-glycosidase F (Boehringer, Mannheim, Germany) at  37 "C for 4 h. 
Reactions were analyzed by 12% SDS-PAGE. 
Zmmunoblot Annlysis-100-ng aliquots of pure APO-1 antigen were 
lyophilized and resuspended in  SDS-PAGE sample buffer containing 
3% SDS. The samples were heated to 95 "C for 5 min and analyzed 
by 12% SDS-PAGE under nonreducing conditions. After electropho- 
resis, proteins  in the gel  were immunoblotted (13) onto  an Immobilon 
polyvinylidene difluoride membrane (Millipore Corp., Bedford, MA) 
with anti-APO-1 (IgG2b)? The immobilized monoclonal antibody 
was detected with horseradish peroxidase-labeled goat-anti-mouse 
IgG2b (Southern Biotechnology Associates, Birmingham, AL. 
Biological Assay for APO-1 Antigenic Activity-2 X lo4 SKW6.4 
cells were incubated in duplicates in  flat  bottom 96-well microtiter 
plates (Technomara, Fernwald, Germany) for 24 h with various 
amounts of purified APO-1 antigen in the presence of either 20 ng/ 
ml isotype-matched nonbinding control monoclonal antibody  FII23 
(3) or 20 ng/ml anti-APO-1. Prevention of cell death (%) was meas- 
J. Dhein, P. T. Daniel, B.  C. Trauth, A. Oehm, P. Moller, and P. 
H. Krammer, submitted for publication. 
ured by [3H]thymidine deoxyribose incorporation after pulsing the 
cells with 0.5 pCi ~f[~H]thymidine d oxyribose (Amersham, Braun- 
schweig, Germany) for the  last 6 h of the culture according to the 
formula C P ~ A P O  .l...ti- ~ ~ ~ - ~ / c ~ m ~ ~ ~ . ~ . ~ l l ~ ~  x 100. 
Amino Acid  Sequencing-10  pg  (210 pmol) of purified APO-1 were 
digested with Asp-N endoproteinase (Boehringer, Mannheim, Ger- 
many) according to the manufacturer's instructions to generate pep- 
tides that were separated by C8 reversed phase using a 2.1 X 100-mm 
Brownlee Aquapore RV-300 column and a  nonlinear 0-85% acetoni- 
trile gradient. The purified peptides were submitted to automated 
Edman degradation using an AB1 470A gas phase Sequenator (Ap- 
plied Biosystems, Weiterstadt, Germany). The program cycles sup- 
plied by  AB1  were modified (one additional coupling step) to increase 
the repetitive yield. The phenylthiohydantoin derivatives of amino 
acids were identified by HPLC in an AB1  120A PTH Analyzer with 
an AB1 900 Data Analysis Module. The  HPLC injection vent was 
equipped with a 100-pl sample loop,  allowing the analysis of 83% of 
the phenylthiohydantoin samples, in order to improve the sensitivity 
of the system. Sequence analyses were carried out on 30-50-pmol 
samples, and repetitive yields of 83-93%  were obtained. 
cDNA  Cloning-The primers 5'-CCGCTGCAGA(T,C)AC(A,G,C, 
T)GC(A,G,T,C)GA(A,G)CA(A,G)AA(A,G)GT (upstream primer, 
sense) and 5'GGGGAATTCTA(A,G,T,C)GC(T,C)TC(T,C)TT(T,C) 
TT (A, G,T, C) C  C (A, G) T G  (downstream primer,  anti-sense) were 
constructed according to the peptide sequences DTAEQKV (up- 
stream, residues 268-275) and HGKKEAY (downstream, residues 
285-291). Reaction mixes of 50 pl (10 mM Tris-HC1, pH 8.3,  50 mM 
KCl, 2.5 mM MgClZ, 0.2 mM each of dGTP, dATP, dGTP,  dTTP) 
contained 50 ng of cDNA prepared from poly(A+)-enriched SKW6.4 
RNA (Amersham Corp., Braunschweig, Germany, cDNA Synthesis 
System Plus-Kit), 100 pmol of each primer mixture and 1 unit of 
Thermus aquaticus DNA polymerase (Perkin-Elmer Cetus Instru- 
ments). 35 cycles (94 "C, 1 min; 48 "C, 2 min; 72 "C, 2 min) were 
performed (14). The amplified DNA  (68 base pairs) was inserted into 
the vector pBluescript-KS  (Stratagene, La Jolla, CA), taking  advan- 
tage of the restriction endonuclease sites  present in the 5'-ends of 
the primers. Transformed bacteria carrying the APO-1-specific insert 
were identified by colony hybridization probing with oligonucleotide 
mixtures derived from internal sequences AA(T,C)TGGCA(T,C)CA 
(A,G)(TT(A,G);CT(A,G,T,C))CA(T,C)GG corresponding to residues 
279-286 (NWHQLHG). A SKW6.4 cDNA library was synthesized 
from 5 pg  of Poly(A+) RNA of SKW6.4 cells using a cDNA synthesis 
kit  (Pharmacia LKB Biotechnology Inc.). Fragments longer than 0.5 
kb were selected by Sepharose CL-4B chromatography and inserted 
into  the EcoRI cut vector X @lo. The cDNA library comprised lo6 
independent clones and had an average insert size of 1 kb. The library 
was amplified once. 
DNA Sequence Analysis-The  2.55-kb fragment was inserted into 
the pBluescript-KS vector, and unidirectional deletions were gener- 
ated using exonuclease III/Sl nuclease (Boehringer, Mannheim, Ger- 
many). Sequences were determined by the dideoxy sequencing method 
(15) using universal sequencing primers  or APO-1-specific primers 
and  the Sequenase DNA Sequencing Kit (U. S. Biochemical Corp.). 
Computer analyses were made with the HUSAR software package of 
the German Cancer Research Center, Heidelberg, Germany. 
Northern Hybridization-Total RNA (10 pg) in sample buffer 
containing 2.2 M formaldehyde were electrophoresed on a 1% agarose 
gel, blotted, and hybridized with the 2.55-kb  cDNA fragment of APO- 
1. The fragment was labeled using the Random Primed DNA Labeling 
Kit (Boehringer, Mannheim, Germany). 
Generation of Stable Transfectants-The Burkitt's lymphoma cell 
line BL 60-P7 (16) was used for electrotransfection, which  was 
performed as described (17). Briefly, 2 X lo" cells and 20  pg  DNA in 
a total volume of 200 p1 of PBS were placed in an electroporation 
chamber with an electrode distance of 4 mm. A high voltage of  200 V 
(capacitance 960 microfarads) was applied with an electropulsing 
device (Bio-Rad). After 5 min on ice,  20  ml  of growth medium were 
added, and cells were incubated for 24 h. Then, 2.5 X 10' cells/ml 
were transferred to 96-, 48-, and 24-well microtiter plates for selection 
of hygromycin B-resistant clones (250 pg/ml, Sigma). APO-1 expres- 
sion was measured 22-31 days after transfection. lo6 cells were treated 
with anti-APO-1 (IgG3) or the isotype-matched nonbinding control 
monoclonal antibody FII23. The second antibody was goat anti-mouse 
Ig fluorescein isothiocyanate-conjugated F(ab'), (70 pg/ml) fragment 
(Dianova, Hamburg, FRG). Fluorescence was measured on a FAC- 
Scan (Becton Dickinson). 
DNA Fragmentation Analysis-Cells (106/ml) were incubated 
either with anti-APO-1 (1 pg/ml) or with FII23 monoclonal antibody 
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(1 wg/ml) in culture medium at 37 "C. At various times,  aliquots of 
IO6 cells were removed,  and DNA was  prepared. Cells were washed 
with  cold PBS and disrupted with  NTE  buffer,  pH 8 (100 mM NaCl, 
10 mM NaC1, 10 mM Tris-HC1, 1 mM EDTA) containing 1% SDS 
and proteinase K (0.2 mg/ml). After incubation for 24 h at 37 "C, 
samples were extracted twice with phenol  plus chloroform (l:l, v/v) 
and precipitated by ethanol.  The DNA was dissolved in 50 ml of NTE 
buffer and digested with ribonuclease (1 mg/ml) at 37 "C for 30 min. 
Samples were analyzed on a 1.8% agarose gel in the presence of 0.5 
pg/ml ethidium bromide (3). 
RESULTS 
Purification of the APO-1 Antigen-APO-1 was purified 
following the purification procedure outlined in Fig. 1. Mem- 
branes of SKW6.4 B lymphoblastoid cells were solubilized 
with sodium deoxycholate using a deoxycho1ate:protein ratio 
(w/w) of 7.51. The sodium deoxycholate extract with no 
detectable APO-1 antigenic activity was loaded onto an  anti- 
APO-1 affinity column and 3.3 x IO6 units of APO-1 antigenic 
activity were eluted with diethylamine/HCl, pH 11.5 (Fig. 
2 4 ) .  Purification to homogeneity was achieved by two con- 
secutive chromatographic separations by reversed phase 
HPLC (Fig. 2B). There was some loss of antigenic activity at 
this step, since only 1.5 X lo4 units of APO-1 antigenic activity 
was eluted from the second HPLC column (Table I). Fig.  2C 
shows the analysis of the purified APO-1  antigen by SDS- 
PAGE and silver staining  after affinity chromatography (lane 
1 ) and  the  first (lane 2) and  the second (lane 3) round of 
reversed phase  HPLC.  A single band of apparent M ,  48,000 
was revealed for the purified APO-1  antigen  under nonreduc- 
ing conditions. After reduction, the APO-1 protein  had  a M ,  
of 51,000 indicating that  the APO-1 molecule consists of a 
single polypeptide chain with intramolecular disulfide bonds 
(Fig. 2 0 ,  lane 1 ). The purified APO-1 molecule  was identified 
as a glycoprotein with 8-kDa N-glycosidic-linked polysaccha- 
rides, representing 16% of the  total protein. Fig. 20, lane 2 
shows the 43-kDa APO-1 protein  after  treatment with endo- 
proteinase FIN-glycosidase F under reducing conditions. De- 
glycosylation of the APO-1  protein  under nonreducing con- 
ditions showed no decrease in molecular weight (data not 
shown). A 48-kDa band specific for APO-1 was also stained 
in a  Western blot analysis under nonreducing conditions (Fig. 
3A, lane 2). Under reducing conditions, the Western blot did 
not develop (data not shown), indicating that the epitope 
recognized by anti-APO-1 is dependent on intramolecular 
disulfide bonds. Chromatofocusing on  Mono-P revealed that 
APO-1 has a PI of 5.4-5.7 (data not shown). The purified 
Membranes of SKW6.4 cells 
1 dissolved IIL: lOmMTRIS/HClpHS.l. 2% sodium deoxycholate 
I 100.000 x g 
t 
Sodium deoxycholate -act 
1 
1 
ann-NO- I 
aelnlty column 
Elutlon: 50 mM diethylamine/HCl. pH 11.5. 
0.1% sodlum deoxycholate 
2 x reversed  phase HPLC 
Elutlon 59% acetommle. 0.1% billuoroacetic  acld 
FIG. 1. Flow sheet for the  purification of the APO-1 anti- 
gen. 
APO-1  protein was capable of preventing  anti-APO-1 induced 
growth inhibition  and apoptosis of SKW6.4 cells (Fig. 3B). 
Isolation and Characterization of a cDNA  Clone for the APO- 
1 Antigen-An N-terminal amino acid sequence of the puri- 
fied APO-1 protein was not obtained, indicating that  the N 
terminus was blocked. Therefore, 10 pg of APO-1 protein were 
cleaved by Asp-N endoproteinase. Resulting peptides were 
separated by reversed phase HPLC and were subjected to 
amino acid analysis (Table 11). The sequence information of 
peptide 1 was used to synthesize short degenerate oligonucle- 
otides. These oligonucleotides were used as primers in polym- 
erase  chain reaction with SKW6.4 cDNA, and  an unambigu- 
ous cDNA probe matching one of the sequenced APO-1 pep- 
tides was obtained. With  this probe, four hybridizing plaques 
out of 1 X lo6 plaques were identified in an SKW6.4  cDNA 
library. The clone with the longest insert was analyzed fur- 
ther. A single open reading frame of 1005 nucleotides was 
found, starting with an ATG (nucleotide 221) that  is preceded 
by an in-frame TGA termination codon (nucleotides 62-64). 
The sequence flanking the assigned ATG (CAACCATGC) 
contains  7 of 9 residues identical with the translation  initia- 
tion consensus sequence (18). The open reading frame pre- 
dicts  a  protein  containing 335 amino acids with typical fea- 
tures of a  transmembrane  protein (Fig.  4).  Amino acids 1-16 
are hydrophobic and probably constitute  a leader peptide with 
a putative cleavage point between A16 and R17 (19). The 
mature  protein  has  a predicted molecular mass of  36 kDa. A 
second hydrophobic region was found at position 172-190, 
flanked on  both sides with positively charged residues (R171 
and KRKlg3) indicative of a  transmembrane region. The N- 
terminal 155 amino acids of the mature  protein  contain 18 
cysteine residues and two potential N-linked glycosylation 
sites. The C-terminal 145 amino acids represent the putative 
intracellular part of APO-1. 
The deduced APO-1 protein sequence revealed significant 
sequence similarity to the cysteine-rich region of the low 
affinity nerve growth factor  (NGF) receptor (20), the B cell 
activation antigen CD40 (21), both types of TNF receptor 
(22-241, the rat T cell activation antigen OX40 (25), the 
deduced protein sequence of the murine cDNA 4-1BB (26) 
expressed upon T cell activation, and  the Shope fibromavirus 
T2 protein (27). Furthermore, the APO-1 protein sequence 
was found to be identical with the recently published sequence 
of the  Fas antigen  (6). A consensus alignment of the cysteine- 
rich domains is shown in Fig. 5A. Sequence similarity was 
also found when the intracellular domains of APO-1,  CD40, 
NGF receptor, and  the  TNF receptor sequences were com- 
pared (Fig. 5B). A threonine residue implicated in CD40 
signaling (Tzs4) (28) is also conserved in TNF receptor 1 (T3") 
and  in APO-1 (TZ4l). 
Functional Expression of the APO-1 Antigen-The  cDNA 
of APO-1 was used to generate stable  transfectants  in  Burk- 
itt's lymphoma BL60-P7 cells (primarily APO-1 negative and 
APO-1 mRNA negative (see Fig. 7, lane 2). A 1070-base pair 
SstII-XbaI  fragment comprising 70 base pairs of the 5'-un- 
translated  and  the  APO-1 coding region  was inserted  into the 
eucaryotic expression vector pKEX-2-XR (29) yielding 
pKEX-2-XR-APO-1. 34  hygromycin B-resistant  ransfec- 
tants were isolated. About 40% of these clones showed im- 
munofluorescence staining specific for APO-1. One APO-1- 
positive (K50) and one APO-1-negative clone (K04) were 
chosen for further analysis. KO4 showed no APO-1 surface 
expression, and  its growth was not  inhibited by the anti-APO- 
1 monoclonal antibody (Fig. 6, A and B ) .  K50  showed  APO- 
1 cell surface expression, and  its growth was inhibited by anti- 
APO-1 (Fig. 6, C and D). Growth inhibition of K50  was  due 
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f  APO-1 from an  anti- APO-1 affinity column. A sodium deoxy- 
cholate extract from membranes of 5 X 10" SKW6.4 cells was loaded onto  an anti-APO-1 IgG3 Sepharose 4B 
affinity column and eluted with 0.05 M diethylamine/HCl, 0.1% sodium deoxycholate, 0.1% NaN3, pH 11.5. Two- 
ml fractions were collected and assayed for pH, absorbance a t  280 nm (.), and antigenic  activity (0). B,  reversed 
phase HPLC of APO-1. Pooled APO-1-containing fractions adjusted to 10% acetonitrile from the  anti-APO-1 
affinity column were chromatographed  on  a PLRP-S column using  a  linear  gradient from 5-70% acetonitrile  in 
0.1% trifluoroacetic acid. The chromatographic separation of first round reversed phase fractions with high 
antigenic  activity  is shown. 0.5-ml fractions were collected and assayed for antigenic  activity (0). C, SDS-PAGE 
showing the purified APO-1. Pooled fractions (100 ng) with high antigenic  activity of the anti-APO-1  affinity 
column ( l a n e  I ) ,  of the first  round HPLC ( l a n e  2), and of the second round HPLC ( l a n e  3) were analyzed by 12% 
SDS-PAGE  under nonreducing conditions. Proteins were visualized by silver-staining. D, deglycosylation of APO- 
1.200 ng samples of purified APO-1  antigen were incubated for 4  h a t  37 "C in the presence of 5% p-mercaptoethanol 
(lane 1 )  and 0.3 units of endoglycosidase FIN-glycosidase F ( l a n e  2). Samples were analyzed by 12% SDS-PAGE. 
Lane 3, enzymes in reaction buffer alone. 
TABLE I 
Purification of  APO-1 
APO-1 antigenic activity was determined by solid phase  ELISA 
with  the anti-APO-1 monoclonal antibody 
Fraction Total Antigenic Specific protein activity actlvity 
mg units X units X mg" 96 
Crude membrane ex- 1167.40" 
Deoxycholate extract 699.20" 
Eluted from affinity 0.410'  33 . 0  814.63 (100) 
tract 
Eluted from first re- 0.060' 55.45  924.17  16.60 
column 
versed Dhase 
HPLC 
Eluted from second 0.0225'  15.00  666 67  4.49 
reversed phase 
HPLC 
a Assayed by the Bradford method (12). 
'Determined from the staining intensity of a standard bovine 
serum albumin band  in  a  silver-stained acrylamide gel. 
to induction of apoptosis, and a DNA ladder was revealed 
after incubation with anti-APO-1. The isotype-matched 
monoclonal antibody FII23, however, did not induce fragmen- 
tation of the genomic  DNA (see Fig.  7). These data indicate 
that  the recombinant protein  is expressed and functionally 
active in the transfected cells. 
Fig. 8 shows in  a  Northern hybridization that APO-1 cDNA 
hybridized predominantly to  an endogenous 2.7-kb and 
weakly to  an endogenous 2.0-kb  mRNA from SKW6.4  cells. 
The APO-1-expressing K50 transfectant showed a major band 
of  2.1 and  a minor band of  2.3 kb, as expected for the spliced 
and unspliced APO-1 RNA transcribed from the transfected 
cDNA expression construct. APO-1 cDNA did not hybridize 
to  the mRNA of APO-1-negative BL60-P7 cells or to mRNA 
of the APO-1 expression negative transfectant clone K04. 
This shows that APO-1 expression of K50  was due to  tran- 
scription of the transfected cDNA and  not due to up-regula- 
tion of expression of an endogenous gene. 
DISCUSSION 
Purification of the APO-1 antigen was achieved from  mem- 
branes of SKW6.4 cells by a combination of membrane solu- 
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FIG. 3. Functional  analysis of the purified APO-1 antigen. 
A ,  Western blot analysis. 100-ng aliquots of pure APO-1 antigen 
eluted a t  59% acetonitrile from the second reversed phase HPLC 
column were lyophilized and resuspended in SDS-PAGE sample 
buffer  containing 3% SDS. The samples were heated to  95 "C  for  5 
min  and analyzed by 12% SDS-PAGE  under  nonreducing conditions. 
After electrophoresis, protein  samples  on  the gel were either silver- 
stained (lane I )  or  immunoblotted (lane 2 )  onto an Immobilon 
polyvinylidene difluoride membrane  with  anti-APO-1 (IgG2b). The 
immobilized  monoclonal antibody was detected  with  horseradish  per- 
oxidase-labeled goat-anti-mouse IgG2b. B, prevention of anti-APO- 
1-induced cell death by purified  APO-1.  2 X lo' SKW6.4  cells were 
incubated  in  duplicates  in  flat  bottom 96-well microtiter  plates for 24 
h  with  various amounts of purified  APO-1 antigen  in  the presence of 
either 20 ng/ml  isotype-matched nonbinding control monoclonal 
antibody  FII23  or 20 ng/ml anti-APO-1.  Prevention of cell death (%) 
was measured by  ["]thymidine deoxyribose incorporation  after puls- 
ing  the cells  with  0.5 pCi of ['Hlthymidine  deoxyribose  for the  last 6 
h of the  culture according to  the formula cpmAPo  .t...ti.APo.,/cpmAp~.I. 
F112R x 100. 
TABLE I1 
Peptide sequences of the APO-I protein 
X. no clear amino acid  was determined  for  this  seouencine cvcle. 
Peptide 1 23 DTAEQKVQLLRNWHQLHGKKEAY 
Peptide 2 15 DSENSNFRNEIQSLV 
Peptide 3 15 DVDLSKYIXXIAXVM 
-mer 
bilization with sodium deoxycholate, affinity chromatography 
on immobilized anti-APO-1, and reversed phase  HPLC. The 
purified APO-1 protein consisted of a single polypeptide chain 
of M ,  48,000 in the nonreduced and M ,  51,000 in the reduced 
state.  The purified APO-1  antigen was found to be a glyco- 
protein with 8-kDa N-glycosidic-linked polysaccharides, rep- 
resenting 16% of the  total protein. The purified polypeptide 
is the antigen recognized  by the anti-APO-1 antibody. This 
is shown by Western  blotting and in  a biological assay where 
purified APO-1 was functionally active and capable to prevent 
anti-APO-1 induced cell death of SKW6.4  cells. Anti-APO-1 
did  not bind to  the reduced APO-1 antigen,  indicating that 
the APO-1 epitope was dependent  on  intramolecular disulfide 
bonds. The enrichment required to yield pure APO-1 antigen 
A 4 
1 HLGIWTLLPL  VLTSVARLSS  KSVNAOVTDI NSKGLELRKT VTTVETONLE GLHHDCOFCH 60 . .  
6 1  KPCPPGERKA RDCTVNGDEP DCVPCOEGKE YTDUHFSSK CRRCRLCDEG H G L E V E I ~  120 
. . .  
1 2 1  RTQNTKCRCK PNFF-C EHCDPCTKCE HGIIKECTLT  SNTKCKEEGS RSNLGWLC1.L 1 8 0  
.. . . . . .  
1 8 1  L L P I P L I W  KRKEVOKTCR KHRKENOGSH ESPTLNPETV A I N L S o v D L s X u r Z . T ! R 2 4 0  
0 100 
FIG. 4. APO-1 amino acid sequence and hydropathy plot. A, 
the deduced APO-1  amino acid  sequence (single  letter  code). Cysteine 
residues are  marked by an asterisk; the  putative leader peptide cleav- 
age site  is indicated by an arrow. The putative  transmembrane  domain 
is underlined, and  potential  N-linked glycosylation sites  are boxed. 
Dashed lines represent  peptide sequences  identified by Edman deg- 
radation. The  entire nucleotide sequence is available upon request 
and  has been  deposited in  the  EMBL  Data  Bank, accession number 
X63717. B, hydropathy profile of the  predicted  APO-1  amino acid 
sequence.  Values were determined  using  the sequence analysis  soft- 
ware  package of the  University of Wisconsin  genetic computer group 
according to Ref. 8. Horizontal axis is  amino acid  number. 
from membranes of SKW6.4 cells could not be determined, 
since the starting material was not active in the APO-1 
specific ELISA. We assume that lack of antigenic activity 
may be due to a masking of the epitope by contaminants  in 
the APO-1 preparation. Taking  into account that 22.5  pg  of 
APO-1 antigen were purified from 5 X 10'' SKW6.4 cells at  
an epitope density of 4 X lo4 APO-1 molecules/SKW6.4  cell 
(3),  a  theoretical yield for the APO-1 purification of 14% can 
be calculated. 
The purified APO-1 protein was digested to generate pep- 
tides that were sequenced by Edman degradation. The se- 
quence information of one of the peptides obtained was  used 
to synthesize oligonucleotides. These oligonucleotides were 
used in  a polymerase chain reaction to synthesize an unam- 
biguous cDNA probe for APO-1. With this probe, a cDNA 
was cloned with a single open reading frame of 1005 nucleo- 
tides, predicting a 335-amino acid protein with a  putative 16 
amino acid leader peptide at  the N-terminal  end and a single 
transmembrane domain. The predicted molecular weight of 
the mature  protein is 36,000 and is in good agreement with 
the 43,000 deglycosylated APO-1 protein. 
The deduced APO-1 protein sequence revealed significant 
sequence similarity to  the cysteine-rich region of the NGF 
receptor, the B-cell activation  antigen CD40, both types of 
TNF receptors, the  rat T cell activation  antigen 0x40, the 
deduced protein sequence of the murine cDNA 4-1BB ex- 
pressed upon T cell activation, and  the Shope fibromavirus 
T2 protein (20-27). While this paper was written, Itoh et al. 
(6) described the sequence of the  Fas antigen obtained after 
expression cloning. Sequence comparison of APO-1 and Fas 
showed complete identity. The  Fas antigen was previously 
defined by the cytolytic monoclonal antibody anti-Fas as a 
200-kDa cell surface protein expressed on various human 
cells, including myeloid cells, T lymphoblastoid cells, and 
diploid fibroblasts. The  anti-Fas antibody (IgM) was estab- 
lished by using the human diploid fibroblast FS-7 cell line as 
an immunogen in mice (7). The cDNA for Fas was stably 
expressed in murine T cell lymphoma WR19L and fibroblast 
L929  cells. The transformed cells were  shown to be  killed by 
anti-FAS antibody by induction of apoptosis (6). 
A common feature of all members of the NGF/TNF recep- 
tor superfamily are repeated cysteine-rich extracellular do- 
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FIG. 5. Sequence  comparison of APO-1 to other members of the TNF  receptor  superfamily.  The 
Multialign and Clustal programs of the University of Wisconsin genetic computer group were applied. A,  consensus 
alignment of the cysteine-rich sequences of APO-1, CD40, NGF receptor, TNF receptor type I, and  TNF receptor 
type 11. Residues are numbered starting with the initiating methionine. Identical residues are boxed. Conserved 
cysteine residues are shown by shading. B, alignment of intracellular protein regions. The abbreviations and 
references are as in A.  
M 1 2 3 4 5 6  ;:/"----' 
qA-D 
x 20 
l @  10' l o *  103 l o '  - 0.075 0.3 1.25 5.0 0 
a, 
H 10 FIG. 7. Anti-APO-1  induced  DNA  fragmentation. BL60-P7 
100 10' 102 101 104  0.075 0.3 1.25 5.0 
cells (lOfi/ml) (lunes 1 and 2 )  and K50 cells (106/ml) (lanes 3-6) were 
incubated with 1 &ml monoclonal antibody for 2 h (lune 41, 4 h 
fluorescence  int nsity d m l  
FIG. 6. Functional expression of the APO-1 antigen in 
BL60-P7 cells. Detection of APO-1 cell surface expression in BL60- 
P7 transfectants. Transfected BL60-P7 cells were stained by indirect 
immunofluorescence with anti-kP0-1 (IgG3, K )  monoclonal antibody. 
A,  KO4 transfectant; C, K50 transfectant. A control antibody FII23 
(IgG3, K) did not bind to  the  transfectants  (data not shown). Anti- 
APO-1-mediated growth inhibition of pKEX-2-XR-APO-1-trans- 
fected BL60-P7 cells. KO4 cells ( B )  and K50 cells (D) were treated 
with  anti-APO-1 monoclonal antibody. 
(lune 5), and 8 h (l&s 1-3 and 6) before cells were  lysed and DNA 
was prepared. DNA was analyzed on  a 1.8% agarose gel. M, marker; 
lunes 1 and 3, isotype-matched control monoclonal antibody FII23; 
lanes 2 and 4-6, anti-APO-1 monoclonal antibody. 
mains. Whereas the two types of TNF receptor, the NGF 
receptor, and  the CD40 antigen comprise four cysteine-rich 
extracellular domains, the APO-1 antigen and the OX40 
antigen have only three such  related domains. A lower degree 
of a new sequence similarity was also found when the  intra- 
cellular domains of APO-1, CD40, NGF receptor, and the 
TNF receptor were compared. Interestingly,  a threonine res- 
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FIG. 8. Northern blot analysis of APO-1 mRNA. Total  RNA 
(10 pg)  from SKW6.4 cells (lane I ) ,  from RL60-P'i cells (lane 2), 
from KO4 cells ( /ane3),  and from  K50  (lane 4 )  cells  were  fractionated 
on  a 1%  agarose gel, blotted,  and  hybridized  with  the  2.55-kh  cDNA 
fragment of APO-1. 
idue implicated in CD40 signaling (T2.54) (28) is also con- 
served in T N F  receptor 1 (T300) and  in  APO-1 (T241). Such 
similarities  might be indicative of a common  mechanism of 
signal  transduction by these molecules. 
The  APO-1 cDNA  was introduced  into  the  human  Burkitt's 
lymphoma line BL60-P7, and APO-1-expressing transfec- 
tants were found to be susceptible toward anti-APO-1 me- 
diated apoptosis. Thus,  these cells seem to provide  all  cellular 
components necessary  for signaling  through APO-1. 
Future  studies will have  to  address  the  intracellular signal 
pathway  and  the physiological  ligand of APO-1.  Such a ligand 
might be  a cytotoxic molecule, directly  inducing  apoptosis,  or 
a survival factor, whose removal leads  to  apoptosis. 
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